消融性放疗在去势抵抗性前列腺癌中的应用
这项单中心随机II期试验纳入≤5个PSMA阳性骨或淋巴结转移的CRPC患者,2:1随机接受转移灶定向治疗(MDT)或观察(OBS),不改变全身治疗。计划中期分析显示1年内PSA进展比例MDT组44% vs OBS组75%(P=0.14,无统计学意义),但MDT组至PSA进展中位时间显著延长(12.4个月 vs 2.9个月,P=0.03)。
要点
- MDT未显著降低1年内PSA进展比例(44% vs 75%,P=0.14)。
- MDT显著延长至PSA进展中位时间(12.4个月 vs 2.9个月,P=0.03)。
- 未达到研究预设的终止标准,计划在多中心继续研究。
核心结论
- 计划中期分析未达到研究方案的终止标准,提示寡转移CRPC的MDT可能延长至PSA进展时间而不立即改变全身治疗。
研究设计与样本
- 单中心、随机、II期临床试验,纳入≤5个PSMA阳性骨或淋巴结转移且在ADT或ADT联合雄激素受体靶向治疗期间出现PSA进展的CRPC患者。
- 共30例患者(OBS组12例,MDT组18例),按2:1随机接受MDT或OBS,不改变全身治疗。
- 主要终点为1年内PSA进展比例,采用意向性治疗原则分析,本次报告预设中期分析结果。
主要发现
- 1年内PSA进展比例:MDT组44% vs OBS组75%(P=0.14,无统计学意义)。
- 至PSA进展中位时间:MDT组12.4个月 vs OBS组2.9个月(P=0.03)。
- 未达到研究预设的终止标准。
临床怎么用
- 对于≤5个PSMA阳性转移的CRPC患者,MDT可在不立即改变全身治疗的情况下延长至PSA进展时间。
- 1年内PSA进展比例未显示显著获益,需等待多中心研究进一步验证。
局限性
- 单中心设计。
- 中期分析时样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration-resistant prostate cancer (CRPC) a single-centre randomised trial was initiated. PATIENTS AND METHODS: This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate-specific membrane antigen-positive bone or lymph node metastases developing prostate-specific antigen (PSA) progression during androgen deprivation (ADT) or ADT and androgen-receptor targeted therapy. Participants were randomised (2:1) to receive metastasis-directed therapy (MDT) or observation (OBS) without changing systemic therapy. The primary endpoint was the proportion of patients having PSA progression within 1 year, with statistical analyses conducted using intention-to-treat principles. Here, results of a planned interim analysis of the primary endpoint are reported. RESULTS: A total of 30 patients (12 in the observation arm and 18 in the MDT arm) were enrolled, PSA progression within 1 year occurred in 44% of the MDT group vs 75% in the OBS group (P = 0.14, not significant). The median time to PSA progression was significantly longer in the MDT arm (12.4 months) compared to the OBS arm (2.9 months, P = 0.03). The pre-defined criteria to discontinue the study were not met. Limitations include the single-centre design and small sample size at interim analysis. CONCLUSION: This pre-planned interim analysis of the primary endpoint did not meet the discontinuation criteria of the study protocol, suggesting that MDT in oligometastatic CRPC may extend the time to PSA progression without immediate change of systemic therapy. The continuation of the study in a multicentre setting is planned (Institutional funding by the TU Dresden, ClinicalTrials.gov identifier: NCT04141709).
引用
- Hölscher T, Lohaus F, Koi L, et al. Ablative radiotherapy in castration-resistant prostate cancer. BJU Int. 2026. PMID: 42389925. doi:10.1111/bju.70368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。